Basal cell forum

(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published online May 21 in the British ...  

The Food and Drug Administration's recent approval of oral vismodegib (Erivedge, Genentech/Roche) introduces an innovative modality for the treatment of basal cell carcinoma (BCC), the most common cancer seen, says Gary Goldenberg, M.D.  

FDA Update: Latest cancer drug approvals and warningsOncology Nurse Advisor• The FDA approved vismodegib (Erivedge) for the treatment of metastatic basal cell carcinoma (BCC) in adults or locally advanced basal cell carcinoma that has recurred following surgery or in those who are not candidates for surgery, and who are not ...  

Basal cell carcinoma on the ear is more frequently found in men, and is significantly more likely to be aggressive, according to a study in the May issue of the Journal of the American Academy of Dermatology.  

Identifying basal cell carcinoma (BCC) subtype on biopsy and excision specimens is the most accurate predictor of invasion depth, according to an April report in the Journal of the American Academy of Dermatology.  

Cyclops Lambs Played Important Role in Vismodegib's ApprovalFamily Practice News Digital NetworkMIAMI BEACH – A new therapy to combat advanced basal cell carcinoma is generating excitement in the few months since its Food and Drug Administration approval. "Vismodegib provides substantial clinical benefit for patients with advanced basal cell ...and more »  

according to the Skin Cancer Foundation. About 90 percent of non-melanoma skin cancers -- typically diagnosed as basal-cell carcinoma or squamous-cell carcinoma -- come from exposure to the sun's ultraviolet rays, foundation statistics say.  

DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/2d8b452a/fda_approves_erive) has announced the addition of GlobalData's new report "FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma" to their offering. FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma is an essential source of information on the approval of...  

Melanoma rates increasing in young womenKETK“Sun exposure is the primary risk factor over all major types of skin cancer be it melanoma, basal cell carcinoma or squamous cell carcinoma," says Dr. Hohnadel. New reports out from several medical journals this month show that young women between the ...and more »  

This research is featured on the cover of the May 2012 issue of Cancer Cell. CHAPEL HILL, N.C. – Multiple research projects – including a 2006 study conducted at the University of North Carolina at Chapel Hill – have used DNA microarray analysis to ...  

May is identified as Skin Cancer Awareness Month. Its goal is to raise awareness and promote prevention of basal cell carcinoma, squamous cell carcinoma and Melanoma skin cancers. Skin cancer is on the rise in Baltimore, and yet it is one of the ...  

Zacks.comVRSEF: Aura Data Published. Operations On-Track.Zacks.comSpecifically, the classes of skin lesions included in the analysis were those diagnosed as malignant or premalignant (ie - malignant melanoma, squamous cell carcinoma, basal cell carcinoma, and actinic keratosis - in aggregate, these represent ...and more »  

In January of 2012, Curis (CRIS) and Roche (RHHBY.PK) were granted FDA approval to market Erivedge, a first-in-class hedgehog inhibitor to treat advanced and metastatic basal cell carcinoma. Roche estimates approximately 14,000 patients in the U.S. with ...